Giant Biotech (02367) announced interim results, adjusted net profit of about 945.5 million yuan, a decrease of 21.5% year-on-year

According to the Zhitong Finance App, Juzi Biotech (02367) announced its 2026 interim results, with revenue of about 2,918 billion yuan, a decrease of 6.3%; gross profit of about 2,318 billion yuan, a decrease of 8.8%; profit attributable to the company's equity shareholders of about 940 million yuan, a decrease of 20.5% year on year; adjusted net profit of about 945.5 million yuan, a decrease of 21.5% year on year; and basic profit per share of 0.89 yuan.

According to the announcement, the decline in revenue was mainly due to phased sales restructuring in the professional skin care product sector. The adjustments were due to the company's long-term business quality and consolidated channel and product competitiveness. With channel operation efficiency, channel structure optimization, and new product growth, the company's business will return to a steady growth trend.

The gross margin fell from 81.7% for the six months ended June 30, 2025 to 79.5% for the six months ended June 30, 2026. Mainly due to the continuous expansion of the company's product matrix, the company expanded more categories of skincare products other than dressings and essences, driving structural fluctuations in overall gross margin. In the future, the company will continue to optimize its product portfolio to cover more user groups, promote the gradual release of scale effects in new categories while increasing revenue scale, and enhance overall resilience to risks and profitability.